Is Inhibition of Nitric Oxide Synthase an Appropriate Therapeutic Target in Sepsis?

  • J. Cohen
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine 1994 book series (YEARBOOK, volume 1994)


Profound unresponsive hypotension characterized by low vascular resistance and which is refractory to vasopressors is one of the cardinal features of established septic shock. In 1987, Moncada et al, and independently, Ignarro et al reported the endothelium derived relaxing factor was indistinguishable from the free radical NO, a finding which has prompted an extraordinary outpouring of investigation into fields as diverse as vascular biology, endocrinology and neuroscience (for review see [1]). Vasodilation is one of the key properties of NO, and from an early stage it has been apparent that NO may play a role in the hypotension of sepsis. If that were true, then it may offer a novel therapeutic target for clinicians faced with a septic patient with refractory hypotension. The principal purpose of this chapter is to consider the evidence implicating NO in the clinical setting of sepsis; however it is necessary first to review briefly the experimental data which underpin the hypothesis.


Nitric Oxide Septic Shock Methylene Blue Septic Patient Systemic Vascular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109–142PubMedGoogle Scholar
  2. 2.
    Geller DA, Lowenstein CJ, Shapiro RA, et al (1993) Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 90: 3491–3495PubMedCrossRefGoogle Scholar
  3. 3.
    Palmer RM, Hickery MS, Charles IG, Moncada S, Bayliss MT (1993) Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 193: 398–405PubMedCrossRefGoogle Scholar
  4. 4.
    Kilbourn RG, Griffith OW (1992) Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 84: 827–831PubMedCrossRefGoogle Scholar
  5. 5.
    Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC (1990) Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 259: H1038 - H1043PubMedGoogle Scholar
  6. 6.
    Kilbourn RG, Gross SS, Jubran A, et al (1990) N-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629–3632PubMedCrossRefGoogle Scholar
  7. 7.
    Klabunde RE, Ritger RC (1991) NG-monomethyl-L-arginine ( NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 178: 1135–1140PubMedCrossRefGoogle Scholar
  8. 8.
    Thiemermann C, Vane JR (1990) Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 182: 591–595PubMedCrossRefGoogle Scholar
  9. 9.
    Cobb JP, Natanson C, Hoffman WD, et al (1992) N“-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 176: 1175–1182PubMedCrossRefGoogle Scholar
  10. 10.
    Lorente JA, Landín L, Renes E, et al (1993) Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med 21: 759–767PubMedCrossRefGoogle Scholar
  11. 11.
    Billiar TR, Curran RD, Harbrecht BG, Stuehr DJ, Demetris AJ, Simmons RL (1990) Modulation of nitrogen oxide synthesis in vivo: N°-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J Leuk Biol 48: 565–569Google Scholar
  12. 12.
    Shultz PJ, Raij L (1992) Endogenously synthesized nitric oxide prevents endotoxininduced glomerular thrombosis. J Clin Invest 90: 1718–1725PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen J, Silva AT (1992) NO inhibitors and septic shock. Lancet 339: 751PubMedCrossRefGoogle Scholar
  14. 14.
    Nava E, Palmer RM, Moncada S (1991) Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 338: 1555–1557PubMedCrossRefGoogle Scholar
  15. 15.
    Teale DM, Atkinson AM (1992) Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone. J Antimic Che-mother 30: 839–842CrossRefGoogle Scholar
  16. 16.
    Evans TE, Carpenter A, Silva AT, Cohen J (1994) Inhibition of nitric oxide synthase in experimental Gram negative sepsis. J Infect Dis (In press)Google Scholar
  17. 17.
    Ochoa JB, Udekwu AO, Billiar TR, et al (1991) Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 214: 621–626PubMedCrossRefGoogle Scholar
  18. 18.
    Evans TE, Carpenter A, Kinderman H, Cohen J (1993) Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 41: 77–81PubMedGoogle Scholar
  19. 19.
    Ochoa JB, Curti B, Peitzman AB, et al (1992) Increased circulating nitrogen oxides after human tumor immunotherapy: Correlation with toxic hemodynamic changes. J Natl Cancer Inst 84: 864–867PubMedCrossRefGoogle Scholar
  20. 20.
    Hibbs JR Jr, Westernfelder C, Taintor R, et al (1992) Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89: 867–877PubMedCrossRefGoogle Scholar
  21. 21.
    Freund H, Ryan JA, Fischer JE (1978) Amino acids derangements in patients with sepsis: Treatment with branched chain amino acid rich infusions. Ann Surg 188: 423–429PubMedCrossRefGoogle Scholar
  22. 22.
    Freund H, Atamian S, Holroyde J, Fischer JE (1979) Plasma amino acids as predictors of the severity and outcome of sepsis. Ann Surg 190: 571–576PubMedCrossRefGoogle Scholar
  23. 23.
    Madden HP, Breslin RJ, Wasserkrug HL, Efron G, Barbul A (1988) Stimulation of T cell immunity by arginine enhances survival in peritonitis. J Surg Res 44: 658–663PubMedCrossRefGoogle Scholar
  24. 24.
    Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338: 1557–1558PubMedCrossRefGoogle Scholar
  25. 25.
    Geroulanos S, Schilling J, Cakmakci M, Jung HH, Largiader F (1992) Inhibition of NO synthesis in septic shock. Lancet 339: 434–435Google Scholar
  26. 26.
    Schneider F, Lutun P, Hasselman M, Stoclet JC, Tempé JD (1992) Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med 18: 309–311PubMedCrossRefGoogle Scholar
  27. 27.
    Schneider F, Lutun P, Runge I, Couchot A, Tempe JD (1992) Effects of soluble guanylyl cyclase inhibition by methylene blue on the loss of vascular responsiveness to norepinephrine in human beings with either gram-negative or gram-positive septic shock. Clin Intensive Care 3 (Suppl): 11 (Abst)Google Scholar
  28. 28.
    Vallance P, Petros A, Lamb G, Leone A, Bennett D (1993) Hemodynamic, biochemical and hematological effects of a nitric oxide synthase inhibitor in patients with septic shock: A randomized study. Endothelium 1 (Suppl): s15 (Abst)Google Scholar
  29. 29.
    Lorente JA, Landín L, De Pablo R, Renes E, Liste D (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21: 1287–1295PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • J. Cohen

There are no affiliations available

Personalised recommendations